The role of nuclear Y-box binding protein 1 as a global marker in drug resistance

Molecular Cancer Therapeutics

Volumn 3, Issue 11, 2004, Pages 1485-1492

  Kuwano, Michihiko ^a   Oda, Yoshinao ^c   Izumi, Hiroto ^b   Yang, Song Ju ^a   Uchiumi, Takeshi ^c   Iwamoto, Yukihide ^c   Toi, Masakazu ^d   Fujii, Teruhiko ^a   Yamana, Hideaki ^a   Kinoshita, Hisafumi ^a   Kamura, Toshiharu ^a   Tsuneyoshi, Masazumi ^c   Yasumoto, Kosei ^b   Kohno, Kimitoshi ^b  

^a KURUME UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APHIDICOLIN; BETA CATENIN; CISPLATIN; CYCLINE; CYTARABINE; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GLYCOPROTEIN P; HEAT SHOCK TRANSCRIPTION FACTOR 1; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MAFOSFAMIDE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEAR FACTOR; NUCLEAR FACTOR Y; NUCLEAR Y BOX BINDING PROTEIN 1; PACLITAXEL; PROTEIN P53; RNA HELICASE; RNA HELICASE A; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

BREAST CANCER; GENE EXPRESSION; HUMAN; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SHORT SURVEY; SYNOVIAL SARCOMA; TRANSCRIPTION REGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; TRANSCRIPTION FACTORS;

EID: 9444259316     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (80)

1. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997;15:4028-33.
2. Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998;36:9-13.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
4. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;15:161-70.
5. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 18:1295-310.
6. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
7. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 1995; 95:2205-14.
8. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (MDR1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987;262:505-8.
9. Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano M. Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. J Biol Chem 1990;15:19690-6.
10. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 2002;64:943-8.
11. Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 1989;165:1415-21.
12. Bates SE, Mickley LA, Chen YN, et al. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol Cell Biol 1989;9:4337-44.
13. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-6.
14. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-62.
15. Miyazaki M, Kohno K, Uchiumi T, et al. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochem Biophys Res Commun 1992;187:677-84.
16. Tanimura H, Kohno K, Sato S, et al. The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem Biophys Res Commun 1992;183:917-24.
17. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-9.
18. Asakuno K, Kohno K, Uchiumi T, et al. Involvement of a DNA binding protein, MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D. Biochem Biophys Res Commun 1994;199:1428-35.
19. Uchiumi T, Kohno K, Tanimura H, et al. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 1993;4:147-57.
20. Izumi H, Imamura T, Nagatani G, et al. Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3′→5′ exonuclease activity. Nucleic Acids Res 2001;29:1200-7.
21. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003;25:691-8.
22. Kuwano M, Uchiumi T, Hayakawa H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94:9-14.
23. Kudo S, Mattei MG, Fukuda M. Characterization of the gene for dbpA, a family member of the nucleic-acid-binding proteins containing a cold-shock domain. Eur J Biochem 1995;231:72-82.
24. Tekur S, Pawlak A, Guellaen G, Hecht NB. Contrin, the human homologue of a germ-cell Y-box-binding protein: cloning, expression, and chromosomal localization. J Androl 1999;20:135-44.
25. Makino Y, Ohga T, Toh S, et al. Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter. Nucleic Acids Res 1996;24:1873-8.
26. Toh S, Nakamura T, Ohga T, et al. Genomic organization of the human Y-box protein (YB-1) gene. Gene 1998;206:93-7.
27. Wolffe AP. Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. Bioessays 1994; 16:245-51.
28. Ladomery M, Sommerville J. A role for Y-box proteins in cell proliferation. Bioessays 1995;17:9-11.
29. Graumann PL, Marahiel MA. A superfamily of proteins that contain the cold-shock domain. Trends Biochem Sci 1998;23:286-90.
30. Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996;56:4224-8.
31. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
32. Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390-4.
33. Stein U, Jurchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001;276:28562-9.
34. Uramoto H, Izumi H, Ise T, et al. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 2002;277:31694-702.
35. Jurchott K, Bergmann S, Stein U, et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003;278:27988-96.
36. Zhang YF, Homer C, Edwards SJ, et al. Nuclear localization of Y-box factor YB-1 requires wild-type p53. Oncogene 2003;22:2782-94.
37. Swamynathan SK, Varma BR, Weber KT, Guntaka RV. Targeted disruption of one allele of the Y-box protein gene, Chk-YB-1b, in DT40 cells results in major defects in cell cycle. Biochem Biophys Res Commun 2002;296:451-7.
38. Shibahara K, Uchiumi T, Fukuda T, et al. Targeted disruption of one allele of Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sci 2004;95:348-53.
39. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999;239:15-27.
40. Sundseth R, MacDonald G, Ting J, King AC. DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 1997;51:963-71.
41. Hu Z, Jin S, Scotto KW. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 2000;275:2979-85.
42. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998;18:4377-84.
43. Morrow CS, Nakagawa M, Goldsmith ME, Madden MJ, Cowan KH. Reversible transcriptional activation of mdr1 by sodium butyrate treatment of human colon cancer cells. J Biol Chem 1994;269:10739-46.
44. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res 2003;63:6942-7.
45. Cornwell MM, Smith DE. Sp1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 1993;268:19505-11.
46. McCoy C, Smith DE, Cornwell MM. 12-O tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Mol Cell Biol 1995;15:6100-8.
47. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher FJ III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 1991;253:1550-3.
48. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Aced Sci U S A 1997; 94:11037-42.
49. Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995;270:1894-8.
50. Strauss BE, Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun 1995; 217:333-40.
51. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001;276: 27716-20.
52. Combates NJ, Kwon PO, Rzepka RW, Cohen D. Involvement of the transcription factor NF-IL6 in phorbol ester induction of P-glycoprotein in U937 cells. Cell Growth Differ 1997;8:213-9.
53. Chen GK, Sale S, Tan T, Ermoian RP, Sikic, BI. CCAAT/enhancer-binding protein β (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 2004;65:906-16.
54. Kioka N, Yamano Y, Komano T, Ueda K. Heat-shock responsive elements in the induction of the multidrug resistance gene (MDR1). FEBS Lett 1992;301:37-40.
55. Vilaboa NE, Galan A, Troyano A, de Blas E, Aller P. Regulation of multidrug resistance 1 (MDR 1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 2000; 275:24970- 6.
56. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/β-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-6.
57. Kuo MT, Liu Z, Wei Y, et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene 2002;21:1945-54.
58. Bentires-Alj M, Barbu V, Fillet M, et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-7.
59. Ogretmen B, Safe AR. Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. Biochemistry 2000;39:194-204.
60. Zhong X, Safa AR. RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells. J Biol Chem 2004;279:17134-41.
61. Bargou RC, Jurchott K, Wegener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3:447-50.
62. Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998;4:2273-7.
63. Oda Y, Ohishi Y, Saito T, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase IIα expression, and with poor prognosis in synovial sarcoma. J Pathol 2003;199: 251-8.
64. Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003;190:191-7.
65. Janz M, Harbeck N, Dettmar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002; 97:278-82.
66. Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999;85:2450-4.
67. Huang X, Ushijima K, Komai K, et al. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 2004;93:287-91.
68. Yahata H, Kobayashi H, Kamura T, et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 2002;128:621-6.
69. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004;59:337-49.
70. Shibao K, Takano H, Nakayama Y, et al. Enhanced coexpression of YB-1 and DNA topoisomerase IIα genes in human colorectal carcinomas. Int J Cancer 1999;83:732-7.
71. Okamoto T, Izumi H, Imamura T, et al. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 2000;19:6194-202.
72. Ise T, Nagatani G, Imamura T, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999;59:342-6.
73. Levenson VV, Davidovich IA, Roninson IB. Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 2000; 60:5027-30.
74. Yao R, Wang Y, Lubet RA, You M. Differentially expressed genes associated with mouse lung tumor progression. Oncogene 2002;21: 5814-21.
75. Ito Y, Yoshida H, Shibahara K, et al. Y-box binding protein expression in thyroid neoplasms: its linkage with anaplastic transformation. Pathol Int 2003;53:429-33.
76. Bader AG, Felts KA, Jiang N, Chang HW, Vogt PK. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A 2003; 100:12384-9.
77. Marenstein DR, Ocampo MT, Chan MK, et al. Stimulation of human endonuclease III by Y box-binding protein 1 (DNA-binding protein B). Interaction between a base excision repair enzyme and a transcription factor. J Biol Chem 2001;276:21242-9.
78. Combates NJ, Rzepka RW, Chen YN, Cohen D. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem 1994;269:29715-9.
79. Chuang SE, Doong SL, Lin MT, Chang AL. Tax of the human T-lymphotropic virus type I transactivates promoter of the MDR-1 gene. Biochem Biophys Res Commun 1997;238:482-6.
80. Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T. Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously downregulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 2003;306:116-20.